drugset / Trial / NCT00940758
Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the dose-limiting toxicity (DLT), toxicity profile, maximum tolerated dose (MTD) and characterize the pharmacokinetics of biweekly PEP02 treatment.
Timeline
- Start
- 2009-06
- Primary completion
- 2012-05
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan Sucrosofate | Other / unclassified | 50 mg/m2 | — |
| Subject | Irinotecan Sucrosofate | Other / unclassified | 100 mg/m2 | — |